Table of Contents
From the Editor
- The promise of molecular biology: Efficacy, safety, wallet depletion
Molecular biology is entering its second wave, with effective but expensive treatments. Recombinant human parathyroid hormone (PTH) is a case in point.
Current Drug Therapy
Recombinant human PTH 1-34 (Forteo): An anabolic drug for osteoporosisWe have an important new drug for osteoporosis. Now who should get it? And who will pay for it?
Im Board Review
- A 34-year-old man with facial droop and dysarthria
A previously well man develops flulike symptoms and neurologic deficits. What is the cause?
Review
- Managing weight gain as a side effect of antidepressant therapy
Some drugs are more apt to cause weight gain than others; one should inform and work with the patient.
- Amiodarone-induced thyrotoxicosis: Diagnostic and therapeutic strategies
It is difficult but important to distinguish the two types of amiodarone-induced thyrotoxicosis.
Review
- Using C-reactive protein to assess cardiovascular disease risk
CRP is now a recognized cardiac test. But who should he tested?
- New advances transform the management of women with abnormal Pap tests
We review the new thin-layer slide system, the new HPV test, the 2001 reporting system for Pap tests, and new management guidelines.
Interpreting Key Trials
- In refractory temporal lobe epilepsy, consider surgery sooner
Epilepsy surgery is perhaps the most underused therapy in all of medicine today.
Commentary
The news from the cancer front is good and bad.